ATE280826T1 - Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen - Google Patents
Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungenInfo
- Publication number
- ATE280826T1 ATE280826T1 AT97904948T AT97904948T ATE280826T1 AT E280826 T1 ATE280826 T1 AT E280826T1 AT 97904948 T AT97904948 T AT 97904948T AT 97904948 T AT97904948 T AT 97904948T AT E280826 T1 ATE280826 T1 AT E280826T1
- Authority
- AT
- Austria
- Prior art keywords
- chemokinceptor
- ckr
- derivatives
- homology
- peptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96870021 | 1996-03-01 | ||
| EP96870102 | 1996-08-06 | ||
| PCT/BE1997/000023 WO1997032019A2 (en) | 1996-03-01 | 1997-02-28 | C-c ckr-5, cc-chemikines receptor, derivatives thereof and their uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE280826T1 true ATE280826T1 (de) | 2004-11-15 |
Family
ID=26144381
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04018812T ATE428785T1 (de) | 1996-03-01 | 1997-02-28 | Aktive und inactive cc-chemokinrezeptoren und nukleinsäuremoleküle, die für diesen rezeptor kodieren |
| AT97904948T ATE280826T1 (de) | 1996-03-01 | 1997-02-28 | Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04018812T ATE428785T1 (de) | 1996-03-01 | 1997-02-28 | Aktive und inactive cc-chemokinrezeptoren und nukleinsäuremoleküle, die für diesen rezeptor kodieren |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US6448375B1 (de) |
| EP (4) | EP0883687B1 (de) |
| JP (2) | JP4117904B2 (de) |
| AT (2) | ATE428785T1 (de) |
| CA (1) | CA2247989C (de) |
| DE (2) | DE69731373T2 (de) |
| DK (2) | DK0883687T3 (de) |
| ES (2) | ES2227672T3 (de) |
| PT (1) | PT883687E (de) |
| WO (1) | WO1997032019A2 (de) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040151719A1 (en) * | 1995-06-06 | 2004-08-05 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor (CCR5) HDGNR10 |
| US6743594B1 (en) | 1995-06-06 | 2004-06-01 | Human Genome Sciences, Inc. | Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5) |
| US6025154A (en) * | 1995-06-06 | 2000-02-15 | Human Genome Sciences, Inc. | Polynucleotides encoding human G-protein chemokine receptor HDGNR10 |
| WO1996041020A1 (en) | 1995-06-07 | 1996-12-19 | Progenics Pharmaceuticals, Inc. | Fluorescence resonance energy transfer screening assay for the identification of hiv-1 envelope glycoprotein-medicated cell |
| US6265184B1 (en) | 1995-12-20 | 2001-07-24 | Icos Corporation | Polynucleotides encoding chemokine receptor 88C |
| US7118859B2 (en) * | 1996-01-17 | 2006-10-10 | Progenics Pharmaceuticals, Inc. | Methods for inhibiting HIV-1 infection |
| US6344545B1 (en) * | 1996-06-14 | 2002-02-05 | Progenics Pharmaceuticals, Inc. | Method for preventing HIV-1 infection of CD4+ cells |
| US7858298B1 (en) | 1996-04-01 | 2010-12-28 | Progenics Pharmaceuticals Inc. | Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists |
| EP0915969A4 (de) | 1996-04-02 | 2002-04-17 | Progenics Pharm Inc | Unterdrückung der infektion von cd4+ zellen durch hiv |
| AU2813297A (en) * | 1996-04-26 | 1997-11-19 | Incyte Pharmaceuticals, Inc. | Mammalian mixed lymphocyte receptors, chemokine receptors {mmlr-ccr} |
| US6258527B1 (en) | 1996-05-20 | 2001-07-10 | The Aaron Diamond Aids Research Center | Methods of identifying g-coupled receptors associated with macrophage-trophic HIV, and diagnostic and therapeutic uses thereof |
| US5939320A (en) * | 1996-05-20 | 1999-08-17 | New York University | G-coupled receptors associated with macrophage-trophic HIV, and diagnostic and therapeutic uses thereof |
| AU3375697A (en) * | 1996-05-28 | 1998-01-05 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Cc chemokine receptor 5, antibodies thereto, transgenic animals |
| JP4183754B2 (ja) * | 1996-06-14 | 2008-11-19 | プロジェニクス・ファーマスーティカルス・インコーポレーテッド | Hiv―1感染を阻害するためのケモカイン受容体の使用 |
| US20040086528A1 (en) * | 1996-06-14 | 2004-05-06 | Progenics Pharmaceuticals, Inc. | Uses of a chemokine receptor for inhibiting HIV-1 infection |
| WO1998005798A1 (en) * | 1996-08-08 | 1998-02-12 | The Aaron Diamond Aids Research Center | Hiv coreceptor mutants |
| US6057102A (en) * | 1996-08-08 | 2000-05-02 | The Aaron Diamond Aids Research Center | HIV coreceptor mutants |
| US6388055B1 (en) * | 1996-10-03 | 2002-05-14 | Smithkline Beecham Corporation | Mouse CC-CKR5 receptor polypeptide |
| US6528625B1 (en) * | 1996-10-28 | 2003-03-04 | Millennium Pharmaceuticals, Inc. | Anti-CCR5 antibodies and kits comprising same |
| AU6271598A (en) * | 1997-02-06 | 1998-08-26 | Epoch Pharmaceuticals, Inc. | Targeted modification of the ccr-5 gene |
| US6153431A (en) * | 1997-05-30 | 2000-11-28 | Fond Mondiale Rech & Prev Sida | Human immunodeficiency virus co-receptor variants associated with resistance to virus infection |
| US6989435B2 (en) | 1997-09-11 | 2006-01-24 | Cambridge University Technical Services Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
| US7067117B1 (en) | 1997-09-11 | 2006-06-27 | Cambridge University Technical Services, Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
| US6204024B1 (en) * | 1997-09-12 | 2001-03-20 | Akzo Nobel N.V. | CCR5 RNA transcription based amplification assay |
| FR2771423A1 (fr) * | 1997-11-21 | 1999-05-28 | Transgene Sa | Vecteurs permettant d'inhiber ou retarder la liaison d'un virus d'immunodeficience et/ou sa penetration dans une cellule cible |
| US6100087A (en) * | 1998-03-11 | 2000-08-08 | City Of Hope | Ribozymes targeted to human CCR5 mRNA |
| US20040228869A1 (en) * | 1998-12-16 | 2004-11-18 | Progenics Pharmaceuticals, Inc. | Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto |
| US20080015348A1 (en) * | 1998-12-16 | 2008-01-17 | Progenics Pharmaceuticals, Inc. | Nucleic acids encoding polypeptides of anti-CCR5 antibodies |
| US7238711B1 (en) | 1999-03-17 | 2007-07-03 | Cambridge University Technical Services Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
| US6329159B1 (en) * | 1999-03-11 | 2001-12-11 | Millennium Pharmaceuticals, Inc. | Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function |
| US7304127B2 (en) * | 1999-08-27 | 2007-12-04 | United States Of America As Represented By The Secretary, Department Of Health And Human Services | Polypeptides that bind HIV gp120 and related nucleic acids, antibodies, compositions, and methods of use |
| CA2385381A1 (en) * | 1999-09-23 | 2001-03-29 | Kenneth Ian Welsh | Susceptibility gene for inflammatory bowel disease |
| WO2001030809A1 (en) * | 1999-10-28 | 2001-05-03 | Nissui Pharmaceutical Co., Ltd. | Cyclic peptides and aids vaccines |
| CA2399593A1 (en) * | 2000-02-09 | 2001-08-16 | Human Genome Sciences, Inc. | Antibodies to ccr5 |
| US7138119B2 (en) | 2000-09-15 | 2006-11-21 | Progenics Pharmaceuticals, Inc. | Compositions and methods for inhibition of HIV-1 infection |
| US7175988B2 (en) | 2001-02-09 | 2007-02-13 | Human Genome Sciences, Inc. | Human G-protein Chemokine Receptor (CCR5) HDGNR10 |
| US7060273B2 (en) * | 2001-04-06 | 2006-06-13 | Progenics Pharmaceuticals, Inc. | Methods for inhibiting HIV-1 infection |
| AU2002359362A1 (en) * | 2001-11-07 | 2003-05-19 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating hematological disorders using 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874 |
| US20030104496A1 (en) * | 2001-11-30 | 2003-06-05 | Cytokinetics, Inc. | Novel motor protein of P. falciparum and methods for its use |
| US7393934B2 (en) | 2001-12-21 | 2008-07-01 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor (CCR5) HDGNR10 |
| US7122185B2 (en) | 2002-02-22 | 2006-10-17 | Progenics Pharmaceuticals, Inc. | Anti-CCR5 antibody |
| CA2559809A1 (en) | 2004-03-12 | 2005-11-10 | Human Genome Sciences, Inc. | Antibodies against human g-protein chemokine receptor (ccr5) hdgnr10 |
| US20060068426A1 (en) * | 2004-08-20 | 2006-03-30 | Tam James P | Cyclic peptides and antibodies thereof |
| US20070026441A1 (en) | 2005-07-22 | 2007-02-01 | Olson William C | Methods for reducing viral load in HIV-1-infected patients |
| KR20080048463A (ko) * | 2005-07-28 | 2008-06-02 | 에덴 바이오테크 엘티디 | 면역 시스템을 재생하는 방법 |
| CA2637600A1 (en) | 2006-01-17 | 2007-07-26 | Health Research, Inc. | Heteroduplex tracking assay |
| JP4569477B2 (ja) | 2006-01-17 | 2010-10-27 | パナソニック株式会社 | スピーカ |
| AR065369A1 (es) | 2007-02-19 | 2009-06-03 | Novartis Ag | Derivados de ciclohexil - amida del acido aril- carboxilico |
| US20080283557A1 (en) * | 2007-05-17 | 2008-11-20 | Julianne Desautels | Spout for food stuff container |
| US20090074766A1 (en) * | 2007-09-14 | 2009-03-19 | Ketas Thomas J | Methods of inhibiting HIV-2 infection |
| EP2425001A4 (de) | 2009-04-30 | 2012-11-14 | Univ California | Anti-hiv-kombinationsvektoren, targeting-vektoren und anwendungsverfahren |
| US20150283266A1 (en) | 2012-08-09 | 2015-10-08 | The Regents Of The University Of California | Cd25 pre-selective combination anti-hiv vectors, targeting vectors, and methods of use |
| JP2016522679A (ja) * | 2013-04-04 | 2016-08-04 | プレジデント アンド フェローズ オブ ハーバード カレッジ | CRISPR/Cas系を用いたゲノム編集の治療的使用 |
| EP3019595A4 (de) | 2013-07-09 | 2016-11-30 | Therapeutische verwendungen einer genomänderung mit crispr-/cas-systemen | |
| US12180263B2 (en) | 2014-11-06 | 2024-12-31 | President And Fellows Of Harvard College | Cells lacking B2M surface expression and methods for allogeneic administration of such cells |
| CN107921148A (zh) | 2015-05-08 | 2018-04-17 | 哈佛学院校长同事会 | 通用供体干细胞和相关方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL105741A0 (en) * | 1992-05-22 | 1993-09-22 | Genta Inc | Pharmaceutical compositions for treating cellular hyperproliferation using interleukin-1 inhibitory compounds |
| EP0740701B1 (de) * | 1994-01-13 | 2006-12-06 | The Regents of the University of California | Monocyten protein rezeptoren aus säugern, mit chemoattraktion auslösender wirkung |
| US5545549A (en) * | 1994-02-03 | 1996-08-13 | Synaptic Pharmaceutical Corporation | DNA encoding a human neuropeptide Y/peptide YY (Y2) receptor and uses thereof |
| GB9501683D0 (en) * | 1995-01-27 | 1995-03-15 | Glaxo Group Ltd | Substances and their uses |
| WO1996039437A1 (en) * | 1995-06-06 | 1996-12-12 | Human Genome Sciences, Inc. | Human g-protein chemokine receptor hdgnr10 |
| US6025154A (en) | 1995-06-06 | 2000-02-15 | Human Genome Sciences, Inc. | Polynucleotides encoding human G-protein chemokine receptor HDGNR10 |
| US6265184B1 (en) * | 1995-12-20 | 2001-07-24 | Icos Corporation | Polynucleotides encoding chemokine receptor 88C |
| AU2813297A (en) * | 1996-04-26 | 1997-11-19 | Incyte Pharmaceuticals, Inc. | Mammalian mixed lymphocyte receptors, chemokine receptors {mmlr-ccr} |
| AU3375697A (en) * | 1996-05-28 | 1998-01-05 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Cc chemokine receptor 5, antibodies thereto, transgenic animals |
| US5928881A (en) | 1996-07-11 | 1999-07-27 | Smithkline Beecham Corporation | Method of identifying agonists and antagonist for CC-CKR5 receptor |
| US6153431A (en) * | 1997-05-30 | 2000-11-28 | Fond Mondiale Rech & Prev Sida | Human immunodeficiency virus co-receptor variants associated with resistance to virus infection |
| US6057182A (en) * | 1997-09-05 | 2000-05-02 | Sarnoff Corporation | Hydrogenation of polysilicon thin film transistors |
-
1997
- 1997-02-28 EP EP97904948A patent/EP0883687B1/de not_active Revoked
- 1997-02-28 CA CA2247989A patent/CA2247989C/en not_active Expired - Lifetime
- 1997-02-28 DE DE69731373T patent/DE69731373T2/de not_active Expired - Lifetime
- 1997-02-28 ES ES97904948T patent/ES2227672T3/es not_active Expired - Lifetime
- 1997-02-28 DK DK97904948T patent/DK0883687T3/da active
- 1997-02-28 AT AT04018812T patent/ATE428785T1/de active
- 1997-02-28 DE DE69739366T patent/DE69739366D1/de not_active Expired - Lifetime
- 1997-02-28 EP EP04018812A patent/EP1482042B1/de not_active Expired - Lifetime
- 1997-02-28 DK DK04018812T patent/DK1482042T3/da active
- 1997-02-28 EP EP01127469A patent/EP1199360A3/de not_active Withdrawn
- 1997-02-28 PT PT97904948T patent/PT883687E/pt unknown
- 1997-02-28 JP JP53047797A patent/JP4117904B2/ja not_active Expired - Lifetime
- 1997-02-28 ES ES04018812T patent/ES2325073T3/es not_active Expired - Lifetime
- 1997-02-28 AT AT97904948T patent/ATE280826T1/de active
- 1997-02-28 EP EP08169488A patent/EP2034023A1/de not_active Withdrawn
- 1997-02-28 WO PCT/BE1997/000023 patent/WO1997032019A2/en not_active Ceased
- 1997-04-09 US US08/833,752 patent/US6448375B1/en not_active Expired - Lifetime
-
2001
- 2001-08-24 US US09/938,703 patent/US6930174B2/en not_active Expired - Fee Related
- 2001-08-24 US US09/938,719 patent/US6692938B2/en not_active Expired - Lifetime
- 2001-08-24 US US09/939,226 patent/US6800447B2/en not_active Expired - Lifetime
-
2003
- 2003-07-02 US US10/612,791 patent/US20040161739A1/en not_active Abandoned
- 2003-09-12 US US10/661,798 patent/US7285390B2/en not_active Expired - Fee Related
-
2008
- 2008-01-22 JP JP2008011942A patent/JP2008179639A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP4117904B2 (ja) | 2008-07-16 |
| EP1482042B1 (de) | 2009-04-15 |
| ATE428785T1 (de) | 2009-05-15 |
| EP0883687B1 (de) | 2004-10-27 |
| ES2325073T3 (es) | 2009-08-25 |
| JP2000505301A (ja) | 2000-05-09 |
| DK1482042T3 (da) | 2009-06-15 |
| US7285390B2 (en) | 2007-10-23 |
| DK0883687T3 (da) | 2005-03-07 |
| US6448375B1 (en) | 2002-09-10 |
| DE69731373D1 (de) | 2004-12-02 |
| CA2247989A1 (en) | 1997-09-04 |
| US6930174B2 (en) | 2005-08-16 |
| US6800447B2 (en) | 2004-10-05 |
| ES2227672T3 (es) | 2005-04-01 |
| WO1997032019A2 (en) | 1997-09-04 |
| US20020106742A1 (en) | 2002-08-08 |
| EP0883687A2 (de) | 1998-12-16 |
| DE69739366D1 (de) | 2009-05-28 |
| US20020110870A1 (en) | 2002-08-15 |
| EP1199360A3 (de) | 2002-05-02 |
| EP1482042A1 (de) | 2004-12-01 |
| PT883687E (pt) | 2005-02-28 |
| EP2034023A1 (de) | 2009-03-11 |
| EP1199360A2 (de) | 2002-04-24 |
| US20020110805A1 (en) | 2002-08-15 |
| US6692938B2 (en) | 2004-02-17 |
| DE69731373T2 (de) | 2006-03-09 |
| US20040110127A1 (en) | 2004-06-10 |
| WO1997032019A3 (en) | 1997-10-23 |
| JP2008179639A (ja) | 2008-08-07 |
| CA2247989C (en) | 2010-12-14 |
| US20040161739A1 (en) | 2004-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE280826T1 (de) | Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen | |
| IL125124A0 (en) | Dimeric forms of the protein fapalpha and uses thereof | |
| ES2178000T3 (es) | Composiciones y metodos para tratar infecciones usando analogos de indolicidina. | |
| NZ335485A (en) | Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof | |
| BG102071A (en) | Minor molecule inhibitors of rotamase enzymic activity | |
| TR200202323T2 (tr) | Akut akciğer harabiyeti ve fibrozitinin alfavß6 antagonistleriyle tedavisi | |
| CY1108610T1 (el) | Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες | |
| ATE234112T1 (de) | Periphäre verabreichung von glp-1 analogen und derivate zur reguleirung der fettleibigkeit | |
| ATE338771T1 (de) | Antagonisten des intestinotrophen glp-2 peptides | |
| ATE177757T1 (de) | Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17 | |
| AR016981A2 (es) | Polipeptidos sinteticos | |
| BG102589A (en) | 3-azetidinylalkylpiperidines or -pyrrolidines as tachykin antagonists | |
| BG102362A (en) | New derivatives of amino acids, their preparation and application | |
| BG106008A (en) | Novel lhrh antagonists with improved solubility characteristics | |
| MXPA03010684A (es) | Peptidos y el uso de los mismos para oscurecer la piel. | |
| TR200001102T2 (tr) | İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları. | |
| ATE474589T1 (de) | Angiogene peptide und ihre verwendungen | |
| TR199901190T2 (xx) | Interferon-(alfa) N�kleik asitlerinin verilmesi ve sentezlenmesi i�in y�ntemler ve bile�imler. | |
| DK1431391T3 (da) | RANTES-mutanter og terapeutiske anvendelser heraf | |
| BR9714376A (pt) | Antagonistas de somatostatina | |
| EA200000909A1 (ru) | ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА | |
| PE20399A1 (es) | Muteina ob | |
| ATE315646T1 (de) | Leukocyten-aktivierender faktor | |
| WO2001092468A3 (en) | Novel compositions for the expression of the human peptide histidine transporter 1 and methods of use thereof | |
| DE3777359D1 (de) | Aminosaeuresequenz des menschlichen alpha 2-plasmininhibitors und cdns sowie diese aminosaeuresequenz codierende genomische dns. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0883687 Country of ref document: EP |